Gaelle Bussac-Rousseau

Creteil, FR 
Creteil, FR 

Overview

Gaelle Bussac-Rousseau practices practicing medicine in Creteil, France.

Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleural Effusion, and EGFR Positive Lung Cancer.

She is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Creteil, France
Other Locations
Paris, France
CHU de Toulouse
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Lorlatinib
Study Phase: Phase 2
View 1 Less Clinical Trial

25 Total Publications

End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysis.
End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysis.
Journal: Translational lung cancer research
Published: March 27, 2026

Frequently Asked Questions about Gaelle Bussac-Rousseau

Is Gaelle Bussac-Rousseau a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Gaelle Bussac-Rousseau is classified as an Experienced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gaelle Bussac-Rousseau participate in research or clinical trials?

Yes. Gaelle Bussac-Rousseau has published 25 articles and abstracts on conditions like Lung Cancer. You can view a list of Gaelle Bussac-Rousseau's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bussac-Rousseau's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile